Sarah Wythe joined ViaNautis as Vice President of Research in December 2023, bringing over 15 years of experience in biotech and academic research. She began her career at Imperial College London, where she conducted groundbreaking research on the cellular immunology of respiratory viruses. Following her PhD, Sarah undertook postdoctoral roles at Barts and The London School of Medicine and Dentistry, and the Kennedy Institute of Rheumatology at the University of Oxford, focusing on immunology and inflammatory diseases.
Her transition to industry started at Oxford Biomedica, where she contributed to CAR-T therapy development. She then joined GammaDelta Therapeutics in London, advancing cellular therapies for oncology and inflammatory diseases. Most recently, Sarah served at Evox Therapeutics, driving innovation in exosome-based therapeutics.
At ViaNautis, Sarah oversees all research activities and preclinical development, leveraging her expertise in advanced therapeutic platforms to guide the company’s pioneering work in genetic medicine.